On Monday, Shares of Seadrill Ltd (NYSE:SDRL), subtract -3.98% and closed at $2.29 in the last trading session. SDRL stock opened its last trade at $2.41 and after floating in a range of $2.28 to $2.46. The company’s Market capitalization is $1.19 Billion with the total Outstanding Shares of 508.76 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.57 and reached to max level of $7.69. Seadrill Limited (“Seadrill”) advises that it is aware of an article published by Bloomberg recently regarding the Company`s ongoing refinancing and recapitalization plans. We refer to our formerly published communications in this regard. The Company remains in negotiations with its stakeholders regarding its refinancing and recapitalization plans and there are no material developments to disclose. This information is subject of the disclosure requirements following section 5-12 of the Norwegian Securities Trading Act.
Gilead Sciences, Inc. (NASDAQ:GILD), subtract -0.15% and closed at $72.64 in the last trading session. GILD stock opened its last trade at $72.54 and after floating in a range of $72.31 to $73.46. The company’s Market capitalization is $95.45 Billion with the total Outstanding Shares of 1.32 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $72.21 and reached to max level of $111.11. Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, in addition to diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners.